Insights
Search Results
Client Highlights
1.16.26
Wilson Sonsini Advises Battle Road Digital on Acquisition by Onebrief
On January 13, 2026, Onebrief, the operating system for modern command, announced that it has acquired Battle Road Digital, a leading defense innovation company applying best-in-class gaming technology to defense and national security challenges. Wilson Sonsini Goodrich & Rosati advised Battle Road Digital on the transaction.
Alerts
7.19.23
California Supreme Court Rules Employees Can Pursue PAGA Claims on Behalf of Other Aggrieved Employees in Court Despite Arbitration Agreement
On July 17, 2023, the California Supreme Court ruled that where an employee has brought a California Private Attorneys General Act (PAGA) action that is comprised of both individual and non-individual claims, a court order compelling arbitration of the employee’s individual claims “does not strip the [employee] of standing as an aggrieved employee to litigate claims on behalf of other employees under PAGA.” The court’s decision in Adolph v. Uber Technologies,1 is bad news for California employers. Just last year the U.S. Supreme Court’s (SCOTUS) decision in Viking River Cruises, Inc. v. Moriana,2 (“Viking River”) held essentially the opposite—that where an enforceable arbitration agreement exists, a court could compel an employee to litigate individual claims in arbitration and that, when it did so, the employee could no longer pursue any non-individual (“representative”) claims in court and the court should dismiss any such non-individual claims. As a result, California employers can expect to see an increase in costly PAGA actions with little hope that their arbitration agreement will reduce the risk of such claims.
Client Highlights
9.02.22
Wilson Sonsini Advises Carbon on Acquisition of ParaMatters
On August 24, 2022, Carbon, a leading 3D printing technology company, announced that it has acquired ParaMatters, a software provider for additive manufacturing. The acquisition expands Carbon's current software capabilities to include topology optimization. Carbon's technology platform now broadens to enable product design and development teams to create better products in less time using a wide variety of materials and production systems. Terms of the transaction were not disclosed.
Client Highlights
8.17.22
Wilson Sonsini Advises Obsidio on Its Acquisition by Boston Scientific
On August 15, 2022, Boston Scientific Corporation announced the acquisition of Obsidio, Inc., a privately-held company that has developed the Gel Embolic Material (GEM) technology used for embolization of blood vessels in the peripheral vasculature. Specific terms of the transaction have not been disclosed.
Client Highlights
5.06.22
Wilson Sonsini Advises Raxium on Acquisition by Google
On May 4, 2022, Google announced it acquired Raxium, an innovator in single panel MicroLED display technologies. Terms of the deal were not disclosed. Wilson Sonsini Goodrich & Rosati represented Raxium in the transaction.
Client Highlights
4.14.22
Wilson Sonsini Advises Sierra Oncology on $1.9 Billion Acquisition by GSK
On April 13, 2022, GlaxoSmithKline plc (GSK) and Sierra Oncology, Inc. announced that they have entered into an agreement under which GSK will acquire Sierra Oncology, a late-stage biopharmaceutical company focused on targeted therapies for the treatment of rare forms of cancer, for $55 per share of common stock in cash, representing an approximate total equity value of $1.9 billion. The per-share price represents a premium of approximately 39 percent to Sierra Oncology’s closing stock price on April 12, 2022, and a premium of approximately 63 percent to Sierra Oncology’s VWAP over the last 30 trading days. Wilson Sonsini Goodrich & Rosati advised Sierra Oncology on the transaction.
Sierra Oncology’s differentiated momelotinib has the potential to address the critical unmet medical needs of myelofibrosis patients with anaemia. In January 2022, Sierra Oncology announced positive topline results from the MOMENTUM phase III trial. The study met all its primary and key secondary endpoints, demonstrating that momelotinib achieved a statistically significant and clinically meaningful benefit on symptoms, splenic response, and anemia. Sierra Oncology is anticipating U.S. regulatory submission in Q2 of this year and EU submission in the second half of 2022.
Wilson Sonsini has also advised Sierra Oncology on a number of recent financing transactions, including public warrant and equity issuances.
Sierra Oncology’s differentiated momelotinib has the potential to address the critical unmet medical needs of myelofibrosis patients with anaemia. In January 2022, Sierra Oncology announced positive topline results from the MOMENTUM phase III trial. The study met all its primary and key secondary endpoints, demonstrating that momelotinib achieved a statistically significant and clinically meaningful benefit on symptoms, splenic response, and anemia. Sierra Oncology is anticipating U.S. regulatory submission in Q2 of this year and EU submission in the second half of 2022.
Wilson Sonsini has also advised Sierra Oncology on a number of recent financing transactions, including public warrant and equity issuances.
Client Highlights
1.13.22
Wilson Sonsini Advises GoFundMe on Acquisition of Classy
On January 13, 2022, GoFundMe, the trusted leader in online fundraising, announced it has signed a definitive agreement to acquire Classy, a leading modern nonprofit fundraising software company. The addition of Classy accelerates opportunities to service the nearly $500 billion U.S. philanthropic market as GoFundMe aims to be the most helpful place in the world. Wilson Sonsini Goodrich & Rosati is advising GoFundMe on the transaction.